Treatment of neovascular age-related macular degeneration with anti-vascular endothelial growth factor drugs: progress from mechanisms to clinical applications

被引:1
|
作者
Cheng, Shizhou [1 ]
Zhang, Shu [1 ]
Huang, Mingyan [1 ]
Liu, Yuxuan [1 ]
Zou, Xunyu [1 ]
Chen, Xiaoming [1 ]
Zhang, Zuhai [1 ]
机构
[1] Yangtze Univ, Dept Ophthalmol, Affiliated Hosp 1, Jingzhou, Peoples R China
关键词
neovascular age-related macular degeneration; vascular endothelial growth factor; treatment; mechanism; clinical application; INTRAVITREAL AFLIBERCEPT INJECTION; RANIBIZUMAB; THERAPY; VEGF; ANGIOGENESIS; OUTCOMES; PHARMACOKINETICS; CLASSIFICATION; DISCOVERY; HISTORY;
D O I
10.3389/fmed.2024.1411278
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Neovascular age-related macular degeneration (nARMD) is an important cause of visual impairment and blindness in the elderly, with choroidal neovascularization in the macula as the main pathological feature. The onset of nARMD is closely related to factors including age, oxidative stress, and lipid metabolism. Vascular endothelial growth factor (VEGF) is an important factor contributing to nARMD as well as choroidal neovascularization and retinal leakage formation. At present, anti-VEGF therapy is the only treatment that improves vision and halts disease progression in most patients, making anti-VEGF drugs a landmark development for nARMD treatment. Although intravitreal injection of anti-VEGF drugs has become the first-line treatment for nARMD, this treatment has many shortcomings including repeated injections, poor or no response in some patients, and complications such as retinal fibrosis. As a result, several new anti-VEGF drugs are being developed. This review provides a discussion of these new anti-VEGF drugs for the treatment of nARMD.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Patient Preferences Associated with Anti-Vascular Endothelial Growth Factor Therapies for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema
    Bhagat, Davis
    Kirby, Breanne
    Bhatt, Harit
    Jager, Rama
    George, Meena
    Sheth, Veeral
    CLINICAL OPHTHALMOLOGY, 2020, 14 : 2975 - 2982
  • [22] Anti-vascular endothelial growth factor for neovascular age-related macular degeneration in 2022: Same, same but different
    Fung, Adrian T.
    CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2022, 50 (03) : 270 - 273
  • [23] GEOGRAPHIC ATROPHY IN PATIENTS RECEIVING ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
    Xu, Luna
    Mrejen, Sarah
    Jung, Jesse J.
    Gallego-Pinazo, Roberto
    Thompson, Desmond
    Marsiglia, Marcela
    Freund, K. Bailey
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2015, 35 (02): : 176 - 186
  • [24] Combination Therapy for Neovascular Age-related Macular Degeneration Refractory to Anti-Vascular Endothelial Growth Factor Agents
    Tozer, Kevin
    Roller, A. Brock
    Chong, Lawrence P.
    Sadda, SriniVas
    Folk, James C.
    Mahajan, Vinit B.
    Russell, Stephen R.
    Boldt, H. Culver
    Sohn, Elliott H.
    OPHTHALMOLOGY, 2013, 120 (10) : 2029 - 2034
  • [25] Efficacy of Anti-Vascular Endothelial Growth Factor Treatment in Neovascular Age-Related Macular Degeneration and Systemic Cardiovascular Risk Factors
    Ladkowska, Joanna
    Gawecki, Maciej
    Szolkiewicz, Marek
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (19)
  • [26] INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION AND POOR VISUAL ACUITY
    Song, Jae Shin
    Kim, Min Seok
    Joo, Kwangsic
    Park, Sang Jun
    Woo, Se Joon
    Park, Kyu Hyung
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2024, 44 (09): : 1486 - 1494
  • [27] Efficacy and Safety of Anti-Vascular Endothelial Growth Factor Monotherapies for Neovascular Age-Related Macular Degeneration: A Mixed Treatment Comparison
    Zhang, Yun
    Gao, Sheng
    Li, Xun
    Huang, Xi
    Zhang, Yi
    Chang, Tiancong
    Cai, Zhaolun
    Zhang, Meixia
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [28] Subgroups and Features of Poor Responders to Anti-Vascular Endothelial Growth Factor Treatment in Eyes with Neovascular Age-Related Macular Degeneration
    Baris, Mine Esen
    Mentes, Jale
    Afrashi, Filiz
    Nalcaci, Serhad
    Akkin, Cezmi
    TURK OFTALMOLOJI DERGISI-TURKISH JOURNAL OF OPHTHALMOLOGY, 2020, 50 (05): : 275 - 282
  • [29] Treatment satisfaction of patients with neovascular age-related macular degeneration treated with anti-vascular endothelial growth factor agents
    Marakis, Theodoros P.
    Koutsandrea, Chrysanthi
    Chatzistefanou, Klio I.
    Tountas, Yannis
    INTERNATIONAL OPHTHALMOLOGY, 2018, 38 (02) : 565 - 576
  • [30] Anti-Vascular Endothelial Growth Factor Treatment Discontinuation and Interval in Neovascular Age-Related Macular Degeneration in the United States
    Bakri, Sophie J.
    Karcher, Helene
    Andersen, Stefen
    Souied, Eric H.
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2022, 242 : 189 - 196